Categories: BioTechDeliveryDevelopmentITPlatformTechnology
Rampart Bioscience is developing a novel non-viral gene therapy platform based on a proprietary HALO DNA technology that has been designed to deliver genetic medicines effectively and durably, and to overcome key limitations and safety concerns of viral and early non-viral gene therapy approaches. Rampart is validating its platform with a novel treatment for hypophosphatasia (HPP), a rare, often fatal genetic disease that prevents bone mineralization. The company has multiple additional programs in development as it aims to develop novel treatment options for patients with genetic diseases.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.10.2023 | Series A | $85M | Forbion |
Mentions in press and media 4
| Date | Title | Description |
| 25.10.2023 | Rampart Bioscience closes $85M Series A Financing to develop DNA-based Medicines | - |
| 24.10.2023 | Rampart Bioscience Announces $85M Series A Financing to Develop Novel DNA-Based Medicines with Veteran Team | - |
| 24.10.2023 | Forbion leads $85M Series A Financing in Rampart Bioscience | Naarden, The Netherlands, October 24, 2023 – Forbion, a leading European life sciences venture capital firm, today announces that it has led an $85 million Series A financing in Rampart Bioscience, Inc., a biotechnology company developing n... |
| 24.10.2023 | Rampart Bioscience Raises $85M in Series A Financing | Rampart Bioscience, a La Jolla, CA-based biotechnology company developing next-generation biologics, raised $85M in Series A funding.
The round was led by Forbion with participation from seed investor OrbiMed and additional new investors RA... |
Reviews 0
